Alert

Recommended Alerts

Sign Up For Alerts

DEA Announces Proposed Expansion of Controlled Substance Monitoring Requirements

On November 2, 2020, the Drug Enforcement Administration (“DEA”) issued a notice of proposed rulemaking expanding the obligations of DEA registrants to monitor and report suspicious orders for controlled substances (the “Proposal”). The Proposal sets forth a two-option framework for reviewing and reporting suspicious orders, adds new reporting and recordkeeping requirements, and expands the scope of suspicious order monitoring obligations to cover certain hospitals, practitioners and other dispensers. Notably, the Proposal asserts that those hospitals, practitioners and dispensers should already be in compliance with the purported requirements.

Read More

Nagoya Protocol on Bioprospecting Moves Closer to International Acceptance

Practices: Life Sciences

Printer-Friendly Version

Cookie Settings